Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1157/13107493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single-Center Experience of 114 Patients.
Hematol Oncol
January 2025
Department of Hematology, Chiba University Hospital, Chiba, Japan.
POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features.
View Article and Find Full Text PDFThe Positive Effects of Training and Time-Restricted Eating in Gut Microbiota Biodiversity in Patients with Multiple Myeloma.
Nutrients
December 2024
Institute for Basic Sciences, Faculty of Physiotherapy, University of Physical Education, 31-571 Krakow, Poland.
Background: The physical activity of different groups of individuals results in the rearrangement of microbiota composition toward a symbiotic microbiota profile. This applies to both healthy and diseased individuals. Multiple myeloma (MM), one of the more common hematological malignancies, predominantly affects older adults.
View Article and Find Full Text PDFSeeking Amyloidosis Very Early: Free light Chain Differentials and IGLV Gene Use as Screening Variables for Light-chain Amyloidosis in λ Monoclonal Gammopathies.
Br J Cancer Res
June 2024
The John Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Background: Early diagnosis of systemic light-chain amyloidosis (AL) is needed because 25% of patients die within months of diagnosis. In patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) of the λ isotype, we explored the use of 2 screening variables: a free light chain difference of 23mg/L between λ and k and presence of IGLV genes that occur more frequently in AL.
Methods: Patients contacted us and we sent HIPAA release and consent forms for discussion by phone.
Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature.
Hematology
December 2025
Clinical Pharmacy Department, King Fahad Medical City, Riyadh, RH, Saudi Arabia.
Multiple Myeloma (MM) is a malignancy characterized by abnormal production of monoclonal immunoglobulins in plasma cells. Bispecific antibodies have emerged as a significant advancement in MM treatment, offering high effectiveness and specificity by targeting different antigens such as BCMA, CD38, and FcRH5. However, the risk of infection poses a major challenge in MM patients, which is thought to be influenced by various factors.
View Article and Find Full Text PDF[IgAκ monoclonal immunoglobulin deposition disease: a case report].
Zhonghua Nei Ke Za Zhi
January 2025
Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing100730, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!